L3VLUP
ProSign in

MTD · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MTDLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MTD
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMTDLLY
Q3 202018 holders, $3.5bn33 holders, $14.1bn
Q4 202016 holders, $3.7bn29 holders, $17.3bn
Q1 202119 holders, $3.3bn24 holders, $23.0bn
Q2 202123 holders, $3.8bn24 holders, $27.8bn
Q3 202120 holders, $3.5bn31 holders, $29.9bn
Q4 202118 holders, $4.4bn31 holders, $34.7bn
Q1 202220 holders, $3.5bn24 holders, $35.3bn
Q2 202220 holders, $2.9bn33 holders, $42.7bn
Q3 202219 holders, $2.7bn31 holders, $43.4bn
Q4 202217 holders, $3.8bn31 holders, $46.6bn
Q1 202324 holders, $4.2bn33 holders, $44.3bn
Q2 202325 holders, $3.4bn37 holders, $59.6bn
Q3 202323 holders, $1.7bn44 holders, $67.6bn
Q4 202324 holders, $2.0bn45 holders, $73.6bn
Q1 202420 holders, $2.0bn41 holders, $95.3bn
Q2 202417 holders, $2.4bn43 holders, $110bn
Q3 202417 holders, $2.6bn45 holders, $107bn
Q4 202417 holders, $1.9bn46 holders, $93.9bn
Q1 202515 holders, $2.0bn42 holders, $98.4bn
Q2 202512 holders, $2.0bn43 holders, $93.2bn
Q3 202511 holders, $2.0bn39 holders, $86.7bn
Q4 202514 holders, $2.5bn41 holders, $123bn
Q1 202610 holders, $2.4bn39 holders, $106bn
Q2 202614 holders, $3.0bn44 holders, $132bn
MTD

Mettler Toledo International

Holders
24
Reported value
$2.0bn
Buyers
15
Sellers
10

Breadth +5 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
45
Reported value
$73.6bn
Buyers
27
Sellers
21

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 51 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MTD (6)

Baillie Gifford & Co, Caxton Associates LLP, PDT Partners LLC, Schonfeld Strategic Advisors LLC, Scion Asset Management LLC, Voloridge Investment Management LLC

Only LLY (27)

Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, MFS Investment Management, Moore Capital Management LP, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Soros Fund Management LLC, Susquehanna International Group LLP, T. Rowe Price Associates Inc, Tiger Global Management LLC, Verition Fund Management LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →